InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Mallon Mark, Chairman & CEO. Director active across 1 companies, notably Neogenomics INC. Aggregated, 5 reports have been logged. Total volume traded: €921k. The latest transaction was filed on 1 March 2022 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations5 total
0142,457 shares0
Common Stock
SEC:0001077183-22-000043:0·
0152,858 shares0
Common Stock
SEC:0001077183-21-000278·
0152,858 shares0
Common Stock
SEC:0001077183-21-000278:0·
€460,61017,000 shares@ €27.09470.043% mcap100.0% of flow
Common Stock
SEC:0001077183-21-000256·
Ideal exit: 2 Sept 2022 (T+270)
€460,61017,000 shares@ €27.09470.043% mcap50.0% of flow
Common Stock
SEC:0001077183-21-000256:0·
Ideal exit: 2 Sept 2022 (T+270)
5 of 5 declarations
About Mallon Mark
Mark Mallon serves as Chief Executive Officer of Neogenomics Inc. In this role, he is responsible for the strategic direction of the company and the management of its operations. Mark plays a key role in formulating growth strategies and establishing relationships with investors. His leadership is essential for ensuring the success and sustainability of Neogenomics.
